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of serious gram-positive infections in humans (with no
animal use counterparts) are in the pharmaceutical pipe-
line (e.g., LY333328 and daptomycin) or have recently been
approved (e.g., linezolid). We hope that a fair balance can be
achieved by the human medical and the animal health and
production communities with regard to the types of antimi-
crobial agents that can be used in each sector.
Thomas R. Shryock
Elanco Animal Health, Greenfield, Indiana, USA
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The Antibiotic Food-Chain Gang
To the Editor: In his reply to my letter (1), Dr. Shryock
states that use of the growth promoter avilamycin, which
confers cross-resistance to other members of the evernino-
mycin class of drugs, was in compliance with the Swann
principles. The Swann report, issued in 1969, recommends
that antibiotics used to treat infections in humans not be
used as animal-food additives (2). The combined efforts of
many scientists were needed to bring about the 1999 ban in
Europe of spiramycin, tylosin, virginiamycin, and bacitra-
cin, each of which confers resistance to antibiotics used in
clinical settings. It appears that more than 30 years was
necessary for the animal-food industry to act in accordance
with the Swann report.
The reasoning in terms of drug structures can be
misleading. The implication is that drugs that are chemical-
ly closely related have the same target of action and are
therefore subject to cross-resistance, and vice versa. For
example, because it has an unusual structure, apramycin (a
4-substituted-2-deoxystreptamin) was used exclusively in
animals in the hope that it would not be recognized by any
of the known aminoglycoside-modifying enzymes (3).
However, enterobacteria of animal origin were resistant to
apramycin by synthesis of a plasmid-mediated 3-N-ami-
noglycoside acetyltransferase type IV, which also confers
resistance to gentamicin (4). Following spread in animal
strains (5), the plasmid was later found in clinical isolates
from hospitalized patients (6).
The use of antibiotics in general should be based on the
mechanisms of resistance in bacteria, rather than on their
chemical makeup. In particular, the concept that resistance
was a class phenomenon rapidly lost favor because of the
extension of the concept of cross-resistance and the in-
creased occurrence of co-resistance.
In classical cross-resistance, a single biochemical
mechanism confers resistance to a single class of drugs: use
of a given antibiotic can select resistance to other members
of the group but not to drugs belonging to other classes.
However, cross-resistance between drug classes can occur
by two mechanisms: overlapping targets and drug efflux. An
example of target overlap is provided by the macrolides,
lincosamides, and streptogramins (MLS), which are chemi-
cally distantly related. However, constitutive methylation of
a single adenine residue in ribosomal RNA confers high-
level resistance to the three classes of antibiotics. This
resistance phenotype is due to the fact that all these
antibiotics have overlapping targets on the ribosome (7).
Active efflux of the drugs outside bacteria has recently been
recognized as a common resistance mechanism (8,9). This
energy-dependent export confers low-level resistance to a
wide variety of antibiotics. The broad substrate specificities
of the pumps account for decreased susceptibility to beta-
lactams, aminoglycosides, tetracyclines, chloramphenicol,
trimethoprim, sulfonamides, fluoroquinolones, and MLS,
among others (9).
In contrast to cross-resistance, co-resistance is due to
the presence in the same host of several mechanisms, each
conferring resistance to a given class of drugs. In addition,
the corresponding genes are often adjacent (physically
linked) and expressed in a coordinated fashion. One of the
most efficient system of this type is represented by the
integrons (10) first described in gram-negative bacilli
(11,12) and more recently found in gram-positive bacteria
(13). Because of the genetic organization resulting in co-
expression of the various genes, use of any antibiotic that is
a substrate for one of the resistance mechanism will co-
select for resistance to the others and thus for maintenance
of the entire gene set. Since cross-resistance means cross-
selection and co-resistance implies co-selection, the use of
any antimicrobial agent is de facto rendered inadequate as
a growth promoter.
I also disagree with the notion that because a member
of an antibiotic class has been misused as a growth promot-
er the class should not be used in the future for human
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therapy; the hierarchy could conceivably be humans first,
animals second, rather than the opposite. For various
reasons, the development of daptomycin  and ramoplanin
has been suspended for several years. If, during this period,
these agents had been used as growth promoters, they
would not now be under development for humans. I would
rather see ramoplanin used for the microbial modulation of
the intestinal tract in immunocompromised patients than
as an animal-food additive.
During the last 30 years, thanks to molecular biology,
enormous progress has been made in understanding the
genetics and biochemistry of resistance. Incorporating this
knowledge for decision-making in problems of public health
importance is timely. I hope that it will not take 30 years
for the pharmaceutical industry to act in agreement.
Patrice Courvalin
Institut Pasteur, Paris, France
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